We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals

59 hedge funds and large institutions have $47.8M invested in Actinium Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

681% more capital inflows, than outflows

Capital inflows: $19.1M | Capital outflows: $2.44M

213% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 8

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

6.2% more ownership

Funds ownership: 11.42% → 17.62% (+6.2%)

5% more funds holding

Funds holding: 56 → 59 (+3)

17% less call options, than puts

Call options by funds: $3.46M | Put options by funds: $4.18M

Holders
59
Holders Change
+3
Holders Change %
+5.36%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
25
Reduced
8
Closed
8
Calls
$3.46​M
Puts
$4.18​M
Net Calls
-⁠$712​K
Net Calls Change
-⁠$1.93​M

ATNM Hedge Fund Activity: Q4 2022 in Review

59 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2022, worth a combined $47.8M — up 125% from $21.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ATNM positions and 8 closed out — a net gain of 2 holders — while 25 added to existing stakes and 8 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $2.43M. The largest seller was Group One Trading, cutting an estimated $713K.

  • 59 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2022, up from 56 in Q3 2022.
  • Funds reported $47.8M of Actinium Pharmaceuticals stock for Q4 2022, up 125% quarter-over-quarter.
  • 10 funds opened new Actinium Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of +2 holders.
  • The largest Actinium Pharmaceuticals buyer in Q4 2022 was D.E. Shaw & Co, an estimated $2.43M added.
  • The largest Actinium Pharmaceuticals seller in Q4 2022 was Group One Trading, an estimated $713K sold.

Based on aggregated 13F filings for Q4 2022.